Sou Hu Cai Jing·2025-08-09 09:37Group 1 - Multiple pharmaceutical companies, including AstraZeneca and Bayer, announced investments totaling approximately 12 billion Mexican pesos (about 4.6 billion RMB) in Mexico, seen as a strategy to circumvent U.S. tariffs through the USMCA [1][8] - Bayer plans to invest around 3 billion Mexican pesos (approximately 1.16 billion RMB) over the next five years to expand local production facilities [3] - AstraZeneca will invest over 2 billion Mexican pesos (about 770 million RMB) in the next two years to enhance clinical research activities and expand production facilities for diabetes and chronic kidney disease medications [4] Group 2 - Boehringer Ingelheim is investing approximately 3.5 billion Mexican pesos to make its tablet production facility in Mexico City the largest globally [6] - A large domestic pharmaceutical company in Mexico announced plans to invest about 3.5 billion Mexican pesos to build a factory in central Mexico, creating over 5,000 jobs [6] - The Mexican government stated that the pharmaceutical industry will receive investments totaling around 12 billion Mexican pesos (about 4.6 billion RMB) [6] Group 3 - President Trump threatened tariffs on imported drugs that could reach up to 250%, with specific measures expected to be announced soon [8] - Products meeting the USMCA preferential tariff treatment conditions, such as drugs produced in Mexico, will not be affected by the new tariff measures [8]